Arbutus Biopharma (ABUS) Retained Earnings: 2009-2025
Historic Retained Earnings for Arbutus Biopharma (ABUS) over the last 15 years, with Sep 2025 value amounting to -$1.4 billion.
- Arbutus Biopharma's Retained Earnings fell 3.17% to -$1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 billion, marking a year-over-year decrease of 3.17%. This contributed to the annual value of -$1.3 billion for FY2024, which is 5.48% down from last year.
- According to the latest figures from Q3 2025, Arbutus Biopharma's Retained Earnings is -$1.4 billion, which was down 0.57% from -$1.4 billion recorded in Q2 2025.
- Arbutus Biopharma's Retained Earnings' 5-year high stood at -$1.1 billion during Q1 2021, with a 5-year trough of -$1.4 billion in Q3 2025.
- For the 3-year period, Arbutus Biopharma's Retained Earnings averaged around -$1.3 billion, with its median value being -$1.3 billion (2024).
- Data for Arbutus Biopharma's Retained Earnings shows a maximum YoY fell of 8.45% (in 2021) over the last 5 years.
- Arbutus Biopharma's Retained Earnings (Quarterly) stood at -$1.1 billion in 2021, then declined by 6.12% to -$1.2 billion in 2022, then dropped by 6.05% to -$1.3 billion in 2023, then decreased by 5.48% to -$1.3 billion in 2024, then fell by 3.17% to -$1.4 billion in 2025.
- Its last three reported values are -$1.4 billion in Q3 2025, -$1.4 billion for Q2 2025, and -$1.4 billion during Q1 2025.